Danyi Wen

      Danyi Wen, President & CEO of Shanghai LIDE Co. Ltd.  Register on 2011, Shanghai LIDE focus on Translational Medicine Services and biomarker development to support new drug R&D. There are two subsidiary companies under Shanghai LIDE: Xian LIDE Biotech and Shanghai LIWEN Clinical Testing Lab.  

      B.S from the Forth Military Medical University M.S from Peking Union Medical University/Chinese Academy of Medical Sciences;MBA from Suffolk University; Post-Doc and Instructor of Medicine at Harvard Medical School (Brigham & Women’s Hospital); 12 years industry experience at Millennium Pharmaceutical, Biogen-Idec.  Returning back to China on 2007 as VP of Biology at Shanghai ChemPartner.  Founded Shanghai LIDE Biotech at the end of 2011.

      Adjourn professor of Beijing Xiehe Hospital and School of Pharmacy of Fudan University; Instructor of Shanghai Technology University. Editor of “Progress in Pharmaceutical Sciences”; Director of PhiRDA, CRO Sub-Group. President of SDDA (Sino-Drug Discovery Association). Associate of Chinese anti-cancer Association (society of Liver, bile, Pancreatic); Vice Group Leader of CMBA Tissue Bank Society, PDX Group.